ClinicaliQ Trial Snapshot
- A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma — Active Not Recruiting • Phase III • Oncology • NCT05625399.
- Subcutaneous injection of two cancer drugs works as well as intravenous infusion for untreated advanced melanoma.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma. Conditions: Melanoma Interventions: Nivolumab + Relatlimab, rHuPH20 Lead Sponsor: Bristol-Myers Squibb Planned Enrollment: 579 participants